In the several clinical trials different anti-angiogenic therapies for gastric cancer, including anti-VEGF or anti-VEGF receptor (VEGFR)-2 monoclonal antibodies, VEGF-Trap and VEGFR tyrosine kinase inhibitors, the anti-VEGFR-2 antibody ramucirumab was demonstrated to prolong overall survival both as a single agent and in combination with paclitaxel as a second-line chemotherapy (36–39). This evidence concerns the gene KDR and gastric cancer.